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THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN HEART 
FAILURE WITH PRESERVED EJECTION FRACTION 
VASSILI GLAZYRINE  
 
ABSTRACT 
 To this day heart failure with preserved ejection fraction (HFpEF) remains 
a poorly understood malady. Half of all heart failure (HF) cases are HFpEF, and 
the prevalence of HF is on the rise. Unlike HF with reduced ejection fraction, 
HFpEF has no treatment options and is often times difficult to diagnose because 
victims of HFpEF often have pre-existing conditions. Vascular endothelial growth 
factor (VEGF) has been implicated in maintaining myocardial health and is 
thought to play a role in HFpEF. We sought to test the hypothesis that VEGF-A 
plays a role in HFpEF in a hypertensive murine model of HFpEF. Using Western 
blot analysis we found that there was an up regulation of VEGF-A in the 
homogenized left ventricle (LV) of our HFpEF mice. Unexpectedly, there was a 
down regulation of VEGF-A in the homogenized tissue from the aorta in those 
mice. To study the circulating levels of VEGF in our HFpEF mice we used an 
ELISA. We found that our HFpEF mice had similar levels of circulating VEGF as 
our control. This suggests that VEGF has paracrine/autocrine role in our HFpEF 
model rather than endocrine, like our human data suggested. To identify the cells 
responsible for the expression profile we saw in the homogenized tissue data we 
looked at the response of adult rat ventricular myocytes (ARVM) and vascular 
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smooth muscle cells (VSMC) to aldosterone stimulation at short (1hr) and long 
(24hr) time points at both physiological (50nm) and pathological (1µm) 
concentrations. To do this analysis we recruited the help of Western blot, ELISA 
and RT-PCR techniques to construct a consistent VEGF expression profile. The 
Western blot ARVM data showed statistically significant (P<0.05) increase in 
VEGF-A to pathological doses of aldosterone, especially at the longer time point. 
When we tested the VSMC using Western blot analysis, we found that the trend 
of our n=1 sample suggested a strong response to the physiological dose of 
aldosterone in the short term. Using the more sensitive ELISA technique to 
measure the VEGF content of our VCMS we increasing our sample size to n=4 
and found no statistically significant  (p=NS) response to aldosterone stimulation 
from the VSMC. However, looking at the trends in the data it is clear that VSMC 
increases VEGF in response to long-term physiological doses of aldosterone. 
This is contrary to what we found using Western blot analysis, so we queried the 
VEGF mRNA from the VSMC to settle the score. Unfortunately, this too proved 
fruitless. The RT-PCR data was not significant and the trend was that of the 
ARVM expression profile. We initially turned to VSMC because we hypothesized 
that they could contribute to the paracrine/autocrine activity similar to what we 
saw in the LV from the ARVM. It is unclear if VSMC play a role in HFpEF 
progression, but their lack of consistent response to aldosterone could potential 
explain the down regulation of VEGF-A we observed in the aorta of our HFpEF 
mice. We initially sough to test the hypothesis that VEGF-A plays a role in our 
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HFpEF mouse model, what we found was that ARVM contribute to localized 
VEGF-A increased production in the LV while in the aorta there is a down 
regulation of VEGF-A in our HFpEF model, we are unable to make any 
conclusion about VSMC response to aldosterone because of insufficient sample 
size. Thus in conclusion, it appears that VEGF-A does play a role in our HFpEF 
model specifically in a paracrine/autocrine manner in the LV where the ARVM 
contributes to the increased production of the cytokine.      	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INTRODUCTION 
 
Heart failure (HF) is a devastating disease that places a substantial 
burden on the healthcare system, the lives of affected individuals, and their 
families. The clinical manifestations of HF include dyspnea, fatigue with exercise 
intolerance as well as fluid retention leading to systemic edema (Yancy et al., 
2013). HF is often difficult to diagnose because of varied symptoms and multiple 
causes of the disease (Yancy et al., 2013). Asymptomatic patients can still have 
HF; because of this, there is no single diagnostic test for HF (Yancy et al., 2013). 
HF involves impaired heart function and dysfunctions of the heart could be 
associated with imperfections of the various layers of the heart wall, the heart 
valves, the great vessels of the heart, or even metabolic conditions such as 
diabetes (Sharma & Kass, 2014; Yancy et al., 2013). Traditionally, ejection 
fraction (EF) served as an important metric with which to diagnose HF and also 
to classify patients with HF into two distinct categories: systolic and diastolic HF 
(Sharma & Kass, 2014). EF measures the percent of blood volume ejected with 
each beat and in turn is a benchmark for left ventricular (LV) performance 
(Sharma & Kass, 2014). LV dysfunction is as variable as the clinical symptoms in 
HF patients. HF patients exhibit a range of LV sizes and a varied percentage of 
left ventricular ejection fraction (LVEF): normal LV and preserved LVEF 
(LVEF≥50%), dilated LV and reduced LVEF (LVEF <40%), as well as a broad 
range in between (Table 1)(Yancy et al., 2013). HF patients with LVEF of less 
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than 40 percent are classified as ‘heart failure with reduced ejection fractions’ 
(HFrEF) patients (Table 1) (Yancy et al., 2013). The HFrEF patient population is 
significantly easier to diagnose and treat (Yancy et al., 2013). ACE (angiotensin 
converting enzyme) inhibitors, aldosterone antagonists, and B-adrenergic 
blockers are three classes of drugs available for HFrEF affected individuals 
(Braunwald, 2013). On the opposite end of the spectrum, patients with ‘heart 
failure with preserved ejection fractions’ (HFpEF) have a relatively normal LVEF 
of greater than or equal to fifty percent. These patients are difficult to diagnose 
and there are no evidence based therapies available to them (Table 1) (Yancy et 
al., 2013).      
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Classification  EF (%)  Description  
I. Heart failure 
with reduced 
ejection fraction 
(HFrEF) ≤40  
Also referred to as systolic HF. Randomized 
controlled trials have mainly enrolled patients 
with HFrEF, and it is only in these patients 
that efficacious therapies have been 
demonstrated to date.  
II. Heart failure 
with preserved 
ejection fraction 
(HFpEF) 
≥50  
Also referred to as diastolic HF. Several 
different criteria have been used to further 
define HFpEF. The diagnosis of HFpEF is 
challenging because it is largely one of 
excluding other potential noncardiac causes 
of symptoms suggestive of HF. To date, 
efficacious therapies have not been identified.  
a. HFpEF, 
borderline 
41 to 49  
These patients fall into a borderline or 
intermediate group. Their characteristics, 
treatment patterns, and outcomes appear 
similar to those of patients with HFpEF.  
b. HFpEF, 
improved 
>40  
It has been recognized that a subset of 
patients with HFpEF previously had HFrEF. 
These patients with improvement or recovery 
in EF may be clinically distinct from those with 
persistently preserved or reduced EF. Further 
research is needed to better characterize 
these patients.  
 
Table 1: Definitions of HFrEF and HFpEF (Yancy et al., 2013) 
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Heart Failure With Preserved Ejection Fraction  
HFpEF is regularly termed diastolic HF because of the abnormalities 
observed during LV relaxation and filling (Horgan, Watson, Glezeva, & Baugh, 
2014). At the end of contraction (systole), the heart engages in a process of 
isovolumetric relaxation in which 80% of the LV filling occurs and marks the 
beginning of diastole. The final stage of diastole is distinguished by atrial 
contraction which fills the remainder of the LV (Figure 1) (Horgan et al., 2014.). 
Diastolic abnormalities are often caused by increased fibrosis of the cardiac 
interstitium and compensatory hypertrophy, leading to reduced compliance of the 
LV. Compliance is the measure of the tissue’s pressure-volume relationship. In 
HFpEF the compliance of the LV is diminished meaning the LV has impaired 
relaxation and greater stiffness, this makes the LV more difficult to fill, drives up 
diastolic pressure, and as a result exacerbates LV hypertrophy (Horgan et 
al.,2014). The 2013 ACCF/AHA Guideline for the Management of Heart Failure 
sites three criteria to make a HFpEF diagnosis: the patient must have clinical 
signs or symptoms of HF, such as dyspnea, fatigue, or exercise intolerance; a 
preserved LVEF; and evidence of LV diastolic dysfunction (Yancy et al., 2013). 
Diastolic dysfunction is a pivotal characteristic in diagnosing HFpEF. Diastolic 
dysfunction is termed as such because it occurs during diastole phase of the 
cardiac cycle where at low filling pressure, the ability for the LV to relax is 
impaired and it is unable to accommodate the necessary blood volume (Horgan 
et al., n.d.). LV function can be determined either by placing an invasive cardiac 
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catheter retrograde into the LV using the atria for access, or by performing an 
non- invasive Doppler echocardiography (Horgan et al.,2014).  
Yet another characteristic of HFpEF is an increase stiffening of both the 
ventricle and the aorta (Borlaug & Kass, 2008). The stiffening of the aorta in 
particular has both pathological and physiological consequences in the ventricle. 
In a healthy individual, the vessels are compliant.  Via ventricular-vascular 
coupling, a healthy heart maintains a normal ejection fraction, prevents a large 
swing in pressure, and as a result avoids both vascular and end-organ damage. 
HFpEF individuals with ventricular-arterial stiffening are sensitive to blood volume 
changes and become hypertensive during periods of stress (Borlaug & Kass, 
2008).     
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Figure 1: Hemodynamic and echocardiographic measurements of left 
ventricular diastolic function (Horgan et al.,2014) 
 
 
 
 
 
	  7 
 Epidemiology 
According to The 2013 ACCF/AHA Guideline for the Management of Heart 
Failure, Americans over the age of 40 have a 20% chance of developing HF in 
their lifetime (Yancy et al., 2013). The incidence of HF raises with age and other 
risk factors such as hypertension, diabetes mellitus, metabolic syndrome, and 
atherosclerotic disease (Yancy et al., 2013). About half off all HF patients have 
HFpEF (Braunwald, 2013).The traditional HFpEF population is perceived to be 
majority white, elderly females with hypertension (Sharma & Kass, 2014). 
However, as more studies are conducted on global HFpEF populace, the 
emerging data suggests patient population is far more diverse than previously 
reported (Horgan et al.,2014). HFpEF is prevalent in a younger, predominantly 
black population, with elevated rates of hypertension, ventricular hypertrophy, 
and obesity (Sharma & Kass, 2014). As greater numbers of diverse populations 
are surveyed, HFpEF seems to disregard not only race, but also sex and 
ethnicity (Sharma & Kass, 2014).    
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Vascular Endothelial Growth Factor  
 Vascular endothelial growth factor (VEGF) is a cytokine that is associated 
with blood-vessel formation in adults (Olsson, Dimberg, Kreuger, & Claesson-
Welsh, 2006).  Recently VEGF has been implicated to have an important role in 
myocardial function, and in turn, HF(Taimeh, Loughran, Birks, & Bolli, 2013). Five 
known mammalian VEGF subtypes are known (Ferrara, Gerber, & LeCouter, 
2003).  Their effects are mediated via three distinct receptor tyrosine kinases as 
seen in Figure 2 (Taimeh et al., 2013). In response to the cytokine stimuli, VEGF 
receptors have a multitude of effects relating to the vasculature: angiogenesis; 
new capillary formation from pre-existing vasculature, arteriogenesis; remodeling 
of pre-existing vessels, and vaculogenesis; and de novo vessel formation 
(Taimeh et al., 2013).  The angiogenic effects are elicited mainly via VEGF-A 
binding to VEGFR-2. Paradoxically, VEGF-A has a much greater affinity for 
VEGFR-1 than VEGFR-2; VEGFR-1 is a known negative regulator of VEGF-A. 
Apart from new vessel formation, VEGF-A interaction with VEGFR-2 has been 
shown to elicit recruitment and homing of stem cells, increase cell survival, 
mediate apoptosis, and play a role in vascular permeability as well as 
vasodilation (Figure 3) (Taimeh et al., 2013). Because of the role VEGF plays in 
the body it could be of great importance in HFpEF. For example VEGF-A in 
particular is proven to be of importance in mediating the compensatory cardiac 
hypertrophy seen in HF (Izumiya et al., 2006). In a cohort of 32 heart failure 
patients with LV dysfunction, the circulating levels of VEGF were markedly 
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increased when compared to control (Table 2) (Martínez-Sales et al., 2011). 
Over 50% of patients with acute HF had a marked increase in circulating VEGF 
levels, while a diminished percentage of patients with stable HF showed the 
same increase (Figure 4) (Martínez-Sales et al., 2011). Furthermore, VEGF 
inhibitors, a new class of anticancer drugs, has shown to most commonly illicit 
hypertension that can lead to LV dysfunction in cancer patients trying this new 
therapy (Tocchetti et al., 2013). VEGF inhibitors increase blood pressure in 
almost 100% of cancer patients that were treated with this type of therapy (Small, 
Montezano, Rios, Savoia, & Touyz, 2014). In addition, the US Food and Drug 
Administration (FDA) found that 19%-67% of patients treated with the various 
FDA approved VEGF inhibitors  developed hypertension (Small et al., 2014). 
Thus, we sought to test the hypothesis that VEGF-A plays a role in HFpEF. 
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Figure 2: Interaction between the five mammalian VEGF molecules and 
their respective receptors (Taimeh et al., 2013) 
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Figure 3: VEGF-A interaction with VEGFR-2 signaling cascade and 
physiological outcomes (Taimeh et al., 2013)   
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Table 2: Increased levels of circulating VEGF as seen in 32 heart failure 
patients with LV dysfunction (Martínez-Sales et al., 2011). 
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Figure 4: Percent of HF patients with acute and stable HF whom have a 
difference in circulating VEGF levels.   (Martínez-Sales et al., 2011). 
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METHODS 
Mouse Model of Heart Failure With Preserved Ejection Fraction  
HFpEF was modeled in wild-type male C57BL/6 mice that underwent 
uninephrectomy at 10-12 weeks.  An ALZET® pumps containg 0.3ug/hr d-
aldosterone (HFpEF) or 0.9% saline (control) were implanted. The mice were 
given 1.0% sodium chloride drinking water for 4-weeks, and had weekly heart 
rate and blood pressure measurements as well LV strcuture and function 
measurments via echocardiography. This is a model of hypertension induced 
HFpEF. After 4 weeks the mice were sacrificed and their LV tissue, aorta, blood, 
spleen, and lungs were collected and apropriately perserved.      
 
Protein Analysis and Quantification  
 After 4 weeks, left ventricular and aortic tissue was collected from wild-
type male C57BL/6 mice that underwent uninephrectomy at 10-12 weeks. The 
tissue was then frozen in liquid nitrogen and stored at -80°C until needed. Tissue 
samples were homogenized using a Bio-Gen PRO200 Homogenizer machine in 
1X lysis buffer containing PMSF. The homogenized tissue was then centrifuged 
and the supernatant collected and stored at -80°C. After thawing the supernatant 
on ice, to each cuvette, 2ul was added into 988ul of diluted dye reagent (BioRad 
Protein Assay Dye Reagent Concentrate, Cat #500-0006, refrigerated). Using a 
Spectrogenic Genesys 5 instrument the total protein concentration was 
determined using 1ml of dH2O as a blank.    
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Western Blot Analysis 
 An equal amount of protein was loaded onto Lonza PAGEr Gold Precast 
12% Tris-Glycine Gels, and then subjected to electrophoresis. Protein content 
was determined via spectrophotometry using a Spectronic Genesys 5 instrument 
as described above. After thawing each sample on ice a calculated amount of 
dye (Laemmli’s SDS-Sample Buffer (4x, reducing) Boston Bioproducts Cat #BP-
110R) was added, samples were then boiled for 5 minutes. Typically, 50-75ug of 
protein was loaded into each well of the polyacrylamide gel. Invitrogen’s 
BenchMark Prestained Protein Ladder was also loaded onto the polyacrylamide 
gel. The BioRad PowerPac Basic power supply was used to perform the protein 
gel electrophoresis. The protein was then transferred onto polyvinyli-dene 
difluoride membrane (GE Healthcare Amersham Hybond) and blocked in a 
solution of 5% milk in TBST. Membranes were then incubated overnight in 4°C 
with VEGF-A P-20 (Santa Cruz Biotechnology sc-1836) purified goat polyclonal 
antibody raised against the N-terminus of VEGF-A of mouse and rat origin. The 
following day membranes were washed with TBST then incubated with 
horseradish peroxidase conjugated secondary antibody donkey anti-goat IgG-
HRP (Santa Cruz Biotechnology sc-2033). The membrane was then developed 
using detection reagents (GE Healthcare Amersham ECL Western Blotting 
Detection Reagent RPN2209), autoradiography film (HyBlot CL autoradiography 
film E3012), and MACHINE INFO. To determine the amount of GAPDH 
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(glyceraldehyde 3-phosphate dehydrogenase), as a loading control measure, the 
membrane was then stripped (ThermoScientific RestoreTM Western Blot 
Stripping Buffer, Product#21059) and re-probed with primary (abcam Anti-
GAPDH antibody-Loading Control ab9484) and secondary (Santa Cruz 
Biotechnology sc-2005 goat anti-mouse IgG-HRP) antibodies, then developed 
using the same method as above.         
             
Isolation and Treatment of Rat Aortic Smooth Muscle Cells 
Rat aortic vascular smooth muscle cells (VSMC) were cultured from adult 
male Sprague-Dawley rats approximately 200-220g in weight. Using scissors and 
tongs the aorta was removed and placed in warm M199 media. In a Nuaire 
biological safety cabinet the fat and connective tissue was removed from the 
aorta, then a longitudinal cut was made and the endothelium was scraped off. 
The aorta was then transferred into a collagenase solution and placed in a Fisher 
Scientific Isotemp CO2 incubator at 37°C for 30 minutes. Next the adventitial 
layer was peeled off using tongs. The remaining tissue was minced into 1-2mm 
size pieces, then digested in a collagenase and elastase solution in a Isotemp 
CO2 incubator at 37°C for 1-2 hours. The remaining cells were centrifuged for 10 
min at 400 x g and then re-suspended in M199 media with 1% P/S, 10% FBS, 
and 2mM L-Glutamine. The cells were plated onto P60 plates and incubated for 1 
week before being passes for the first time. After the second passaged the cells 
were treated with aldosterone and collected at various time points.    
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Isolation and Treatment of Adult Rat Cardiac Myocytes  
 Adult rat ventricular myocytes (ARVM) were isolated from adult male 
Sprague-Dawley rats. The heart was removed then attached to a perfusion pump 
to remove the blood (K-H buffer consisting of 2.36M NaCl, 0.094M KCL, 0.024M 
MgSO4, 0.024M KH2PO4, and 0.5M NaHCO3) and begin the digestion process 
(collagenase and hyaluronidase in K-H buffer). After ~25 min of perfusion the 
heart was transferred to P60 containing trypsin in K-H buffer and digested in a 
shaking 37°C water bath for 30-40 min. The tissue was then pipette up and down 
10 times in a Nuaire biological safety cabinet, then filtered through 80-micron 
mesh gauze and centrifuged. The supernatant was aspirated and the re-
suspended pellet was then ran through BSA. BSA was then aspirated and 
DMEM was added then the cells were plated on P35 plastic culture dishes that 
were coated in laminin solution. The ARVM were allowed to adhere and grow for 
24hrs in Isotemp CO2 incubator at 37°C before treatment with aldosterone and 
collection.  
 
 
Mouse VEGF Immunoassay  
The amount of VEGF in mouse blood serum and rat VSMC lysate were 
determined via VEGF ELISA kit (R&D quantikine ELISA Kit MMV00). After 4 
weeks mouse blood was collected from wild-type male C57BL/6 mice that 
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underwent uninephrectomy at 10-12 weeks then centrifuged for 20 min at 2000 x 
g. Both mouse blood serum and rat VSMC lysate were stored at -80°C until they 
were ready to be used in the ELISA assay. The ELISA kit manufacturer protocol 
was followed. The serum samples were diluted 5-fold as directed, the mouse 
VEGF standard was diluted and loaded onto the plate as prescribed. The plate 
was read via a X machine and Y software was used to interpret the results.     
 
 
RNA Isolation from Adult Rat Vascular Smooth Muscle Cells 
The RNeasy® Lipid Tissue Mini Kit by QIAGEN® was used for RNA 
isolation from adult rat vascular smooth muscle cells. All of manufacturers 
protocols were followed. Growth media was removed from cells, then 1mL of 
TRIzol® Reagent was added and cells were scraped off plate then transferred to 
a clean 1.5mL microfuge tube for storage at -80°C. Samples were thawed then 
0.2mL of chloroform was added. After shaking the cells, they were incubated at 
room temp for 3 min before centrifuging at 12,000g for 15 min at 4°C to remove 
the TRIzol®. The aqueous phase was carefully removed and placed into a new 
2mL collecting tube for RNA isolation. The Qiacube was used according to 
manufacturer’s instructions. Analysis of RNA yield was quantified using an ND-
1000 spectrophotometer and accompanying software.  
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cDNA Reaction Protocol 
 The High-Capacity cDNA Reverse Transcription Kit from Applied 
Biosystems was used for initiating cDNA synthesis. The manufacturers 
suggested protocol was followed. A 2X Master Mix consisting of 10X RT buffer, 
25X dNTP mix, 10X RT random primers, MultiScribe reverse transcriptase and 
water was made. Samples were prepared by adding 10 uL of RNA sample to 10 
uL of the Master Mix and 10 uL of water. Reverse transcription was then 
performed in a thermal cycler in 4 steps: 25°C for 10 min, 37°C for 120 min, 85°C 
for 5 min, then hold at 4°C. At the end of the cycle 20 uL of cDNA was added to 
480 uL of water and stored at -80°C.  
 
Real Time Polymerase Chain Reaction Protocol	  
 The Applied Biosystems ViiA7 Real-Time PCR System was used to 
measure and quantify RNA isolation from adult rat vascular smooth muscle cells. 
In a 96 well plate, VEGF and GAPDH contents were measured in duplicate. In 
each well a 20uL volume consisting of 8uL of sample, 10uL of Sybr® Green, and 
2uL of primer was added. Results were analyzed via the Applied Biosystems 
ViiA7 Real-Time PCR System.	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RESULTS 	  
General  
          VEGF-A expression was examined in the aorta, LV, and serum samples of 
HFpEF mice. The precise characteristics of the HFpEF mouse model used can 
be seen in the November 2014 paper published in Circulation Heart Failure 
entitled Effects of Adiponectin on Calcium Handling Proteins in Heart 
Failure with Preserved Ejection Fraction (Tanaka et al., 2014a). Generally, the 
mice were used to exhibit a hypertension-induced HFpEF model (Tanaka et al., 
2014a). HFpEF mice showed signs of LV hypertrophy and diastolic dysfunction, 
similar to what clinicians observe in the HFpEF patient population (Tanaka et al., 
2014b). To gain insight into the molecular mechanism associated with HFpEF, 
VEGF expression in two distinct rat tissues cultures treated with aldosterone 
were analyzed. Adult rat ventricular myocyte (ARVM) and vascular smooth 
muscle cells (VSMC) were isolated, cultured, then treated with physiological and 
pathological doses of aldosterone at various time points. After collecting and 
lysing the cells, VEGF content was determined using three distinct methods. 
Total VEGF protein content was determined via Western blot analysis and 
enzyme-linked immunosorbent assay (ELISA). The mRNA content in the VSMC 
was determined via real time polymerase chain reaction (RT-PCR) analysis.   
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Vascular Endothelial Growth Factor in Tissue  
In homogenized HFpEF LV mouse tissue (n=5) there was a statistically 
significant increase in VEGF-A expression as compared to the LV tissue of the 
WT mice (n=4) (P<0.05 Figure 5). This confirmed prior studies conducted by 
Izumiya, who found that VEGF promoted the compensatory cardiac hypertrophy 
seen in HFpEF (Izumiya et al., 2006). However, when looking at the 
homogenized aortic tissue of the HFpEF mice, an unfamiliar trend emerged. The 
homogenized aortic tissue data suggests there is a statistically significant 
decrease in VEGF levels in the aorta of HFpEF mice (n=15) when compared to 
the control (n=12) (P<0.05 Figure 6). Sampling a cohort of 15 wild-type male 
C57BL/6 mice infused with aldosterone for four weeks has not only observable 
phenotypic consequences, but also unexpected changes in cytokine levels when 
compared to the 12 wild-type male C57BL/6 mice infused with saline for four 
weeks.   
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Figure 5: VEGF-A Expression in Mouse LV.  HFpEF homogenized LV mouse 
tissue (n=5) was compared to control LV mouse tissue (n=4) via Western blot 
analysis. For the Western blot control Coomassie stain was used. In a two-tailed 
t-test results were significant P<0.05.  
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Figure 6: VEGF-A Expression in Mouse Aorta. HFpEF homogenized aortic 
mouse tissue (n=15) was compared to control aortic mouse tissue (n=12) via 
Western blot analysis. For the Western blot control GAPDH anti-body was used. 
In a two-tailed t-test results were significant P<0.05. 
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Vascular Endothelial Growth Factor in Serum  
Along with tissue, the blood from the HFpEF (n=15) and control (n=12) 
mice was collected. The blood from the mice was collected via the heart using a 
syringe, and then centrifuged to isolate the serum. Human serum was venously 
collected from consenting HFpEF patients (n=16) and 3 control patients (n=3) 
with no history of cardiac disease. The human serum data suggested there would 
be statistically significant compensatory increase (419.6 ng/mL vs. 68.3 ng/mL) in 
circulating VEGF in the HFpEF population (P<0.05 Figure 7). However, the 
results of the mouse blood serum data were quite different. There seems to be 
no difference between blood serum VEGF level in HFpEF vs. control (P=NS 
Figure 8). The large cohort of 12 controls and 15 HFpEF mice had almost 
identical VEGF mean serum levels (53.6 pg/mL vs 53.8 pg/mL).    
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Figure 7: VEGF in Human Blood Serum. VEGF concentration (pg/mL) is 
measured in HFpEF human blood serum (n=16) and control human blood serum 
(n=3) samples via ELISA. In a two-tailed t-test results were significant P<0.05. 
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Figure 8: VEGF in Mouse Blood Serum. VEGF concentration (pg/mL) is 
measured in HFpEF mouse blood serum (n=15) and control mouse blood serum 
(n=12) samples via ELISA. In a two-tailed t-test results were not significant 
P=NS. 
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Vascular Endothelial Growth Factor in Adult Rat Ventricular Myocytes  
 The ARVM’s were isolated from the heart tissue of adult male Sprague-
Dawley rats. After culturing the ARVM’s (n=3) in a CO2 incubator at 37°C, they 
were treated with physiological (50nm) and pathological (1um) doses of 
aldosterone. At both doses, long term (24hr) and short term (1hr) responses to 
aldosterone treatment were measured. Control ARVM not treated with 
aldosterone were in incubated and measured in duplicate n=6. In the 
physiological range (50nm) only long term exposure to aldosterone elicits a 
statistically significant increase in VEGF (P<0.05 Figure 9). However, when given 
a higher does (1um) of aldosterone the ARVM’s had a statistically significant 
increase in VEGF independent of time (P<0.05 Figure 9). The most significant 
increase in VEGF expression came from the group of ARVM’s treated with a 
pathological dose of aldosterone for 24hrs. This group had almost three times the 
amount of VEGF when compared to control. Thus higher doses of aldosterone 
are able to stimulate VEGF-A as seen in ARVM. 
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Figure 9: VEGF-A in Aldosterone Treated ARVM. Cultured ARVM (n=3) were 
treated with 50nm and 1um aldosterone for 1hr and 24hr. VEGF-A content was 
measured via Western blot analysis and compared to control (n=6). For the 
Western blot control GAPDH anti-body was used. In a two-tailed t-test results 
were significant P<0.05 (*). 
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Vascular Endothelial Growth Factor in Vascular Smooth Muscle Cells 
 The VSMC’s were isolated form the aorta of adult male Sprague-Dawley 
rats. The isolated VSMC’s were placed on a P60 plate, then allowed to adhere 
and grown for a week in a CO2 incubator at 37°C. Upon reaching 90% 
confluence, one plate was passed to four, then allowed to grow for three 
additional days. After the second passage the VSMC’s were treated with 
physiological (50nm, 100nm) and pathological (1µm) doses of aldosterone. Both 
long (24hr, 48hr) and short (1hr) term exposure to aldosterone were measured. 
In the initial experiment the quantity of VEGF was determined via western blot 
(P=NS Figure 10). Due to the small sample size (n=1) the experiment did not 
yield statistically significant results, however, a trend was observed and a more 
sample was queried via ELISA. The western blot data hinted that at treatment of 
both physiological (100nm) and pathological (1µm) concentrations of 
aldosterone, VSMC responded by increasing VEGF production in the short term 
(P=NS Figure 10). To test this hypothesis the sample size was increased to N=4, 
a lower physiological dose of aldosterone was tested (50nm), and the 48hr 
exposure was removed from the protocol. The VEGF protein content (pg/mL) 
from the four VSMC samples was then tested using an R&D quantikine ELISA Kit 
(P=NS Figure 11). Unfortunately, no statistically significant trend appeared 
(P=NS Figure 11). It does seem that in the long term (24hr) at physiological 
concentrations (50nm and 100nm) the VSMC increase their VEGF production 
(P=NS Figure 11). This data was contrary to what was observed when 
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performing the Western blot analysis (P=NS Figure 10). RT-PCR was used to 
determine the subtle changes in mRNA quantity of VSMC exposed to 
physiological (50nm) and pathological (1µm) aldosterone concentrations at both 
long (24hr) and short (1hr) time intervals. VEGF, GAPDH, and HPRT 
(hypoxanthine-guanine phosphoribosyltransferase) primers from Integrated 
DNA Technologies were used. GAPDH and HPRT served as controls for the RT-
PCR data analysis. The data as presented in Figure 12 suggests that VSMC 
respond most to pathological (1µm) long (24hr) exposure to aldosterone (P=NS 
Figure 12). The RT-PCR data is of not significant because of the small sample 
size and further muddles both the western blot and ELISA VSMC data.    
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Figure 10: VSMC Western Blot Measuring VEGF-A. VEGF-A expression 
measure in cultured adult rat VSMC (n=1) treated with 100nm and 1um 
aldosterone for 1hr, 24hr, and 48hr time periods. For the Western blot control 
GAPDH anti-body was used. In a two-tailed t-test results were not significant 
P=NS. 
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Figure 11: VSMC ELISA Measuring VEGF. VEGF concentration (pg/mL) was 
measured in cultured adult rat VSMC (n=4) treated with 50nm, 100nm, and 1um 
aldosterone at 1hr and 24hr time points. In a two-tailed t-test results were not 
significant P=NS. 
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Figure 12: VSMC RT-PCT Measuring VEGF. VEGF mRNA content was 
measured in cultured adult rat VSMC (n=1) treated with 50nm and 1um 
aldosterone at 1hr and 24hr time points. In a two-tailed t-test results were not 
significant P=NS. 
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DISCUSSION 
 
In this study, we sought to test the hypothesis that VEGF-A plays a role in 
HFpEF. VEGF-A is essential in maintaining regular myocardial function, the lack 
of which, causes the heart to transition from hypertrophy to HF as shown by 
Izumiya et al. (Giordano et al., 2001; Izumiya et al., 2006). In cancer patients 
treated with VEGF inhibitors, Tocchetti et al. found they developed a multitude of 
cardiac issues, such as hypertension and diastolic dysfunction (Taimeh et al., 
2013). Borlaug and Kass characterized the importance of ventricular-vascular 
coupling in the progression of HF, which motivated our investigation to query 
beyond the heart and examine the vasculature (Borlaug & Kass, 2008). We 
aimed to study the importance of VEGF-A in the heart, aorta, and serum of a 
hypertension-induced HFpEF mouse model. We tested homogenized tissue 
samples of aldosterone-infused wild type mice that developed HFpEF, evident by 
their preserved ejection fraction, hypertension, LV hypertrophy, and diastolic 
dysfunction. To gain insight into the molecular basis for the phenotypic changes 
we observed in the ventricle and vasculature of HFpEF mice, we cultured ARVM 
and VSMC, treated them with aldosterone, then observed changes in VEGF-A at 
both the protein and mRNA level using various molecular biology techniques. 
In a first approach we analyzed VEGF-A in the homogenized ventricle and 
aorta of our HFpEF mice and compared them with sham mice using Western blot 
analysis. After 4 weeks of chronic exposure to aldosterone, the mice began to 
develop HFpEF. HFpEF mice had an increase in VEGF-A expression in the 
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ventricle, and a decrease in the aorta when compared to control. The former 
finding was somewhat expected as it is clear VEGF-A plays an essential role in 
maintaining cardiac function (Giordano et al., 2001; Izumiya et al., 2006). 
However, the latter finding was both novel and surprising. Other studies suggest 
that due to the ventricular-vascular relationship, a synergistic increase in VEGF-A 
in the aorta should appear (Borlaug & Kass, 2008; Taimeh et al., 2013). With the 
lack of endogenous VEGF-A production in the vasculature we questioned if there 
was a compensatory increase in systemic VEGF-A production.  
A paper published in 2011 by Martínez-Sales et al. led us to look at the 
serum VEGF-A levels in both the HFpEF patient population as well as our 
HFpEF mouse model (Martínez-Sales et al., 2011). We expected to confirm 
Martínez-Sales et al. findings and confirm an increase in VEGF-A serum levels in 
both the HFpEF patient population and the HFpEF mice. However, in only the 
former group that finding held true. Of the sixteen HFpEF patients whose serum 
was analyzed, we found that on average they had a four-fold increase in serum 
VEGF-A when compared to control. The HFpEF mouse VEGF-A sera were no 
different from control. In fact, their VEGF-A serum levels were almost identical 
(53.6 pg/mL vs 53.8 pg/mL). The curious phenotype of our HFpEF mice 
observed thus far is one of evident paracrine and autocrine effects of VEGF-A in 
the heart, lack of endocrine VEGF-A secretion, and failure of endogenous 
production of VEGF-A in the vasculature. A molecular biological explanation to 
the findings was warranted.   
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In the next phase of our study, we attempted to narrow down the possible 
cell types that could be implicated in the VEGF-A expression profiles we 
observed. Due to their role in the heart’s VEGF paracrine signaling, we isolated 
and examined ARVM (Giordano et al., 2001). In the aorta we chose to study the 
VSMC because of their known response to aldosterone (Giordano et al., 2001; 
Pruthi et al., 2014). After exposing both cell types to physiological and 
pathological concentrations of aldosterone at long and short intervals, it was 
interesting to find ARVM responded to both concentrations of aldosterone, and 
the longer the exposure, the greater the increase in VEGF-A expression. 
Conversely, the single set of VSMC tested using western blot analysis we 
observed a short-term response to aldosterone at only the physiological range. 
The ARVM data corroborated what we observed in the homogenized ventricle 
data. With the VSMC data we could now explain the reason we saw a decrease 
in VEGF-A in our homogenized aorta. Potentially what we observed in the 
vasculature was a temporal relationship between aldosterone stimulation and 
VEGF-A expression. With VEGF-A elevated for only a short period of time in the 
VSMC, the cytokine levels then diminished to the miniscule amounts that we 
detected when western blotting our homogenized aorta. This speculation led us 
to further explore VSMC expression of VEGF. Although we saw a positive trend 
in the initial Western blot data, it was not significant due to the small sample size. 
To remedy this, in a separate experiment, we isolated and treated three more 
vascular smooth muscle cell lines with aldosterone, then measured their VEGF 
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expression via ELISA. Unfortunately, the ELISA data did not corroborate what we 
previously found in our Western blot experiment. The ELISA data suggests 
VSMC respond most to long-term physiological exposure to aldosterone, not 
short-term treatment. This trend is not statistically significant; an even larger 
sample size needs to be queried. The protein expression in the VSMC has led us 
in two different directions: the Western blot data supports our hypothesis 
regarding the homogenized tissue data, while the ELISA data calls for a re-
analysis of our results. To help settle this discrepancy we turned to RT-PCR to 
look at the mRNA content in our aldosterone treated VSMC. What we found 
further complicated our VSMC aldosterone response hypothesis. The RT-PCR 
data showed a trend that hinted at the possibility that VSMC, at least at the 
mRNA level, respond most to long-term pathological doses of aldosterone while 
the physiological doses have little to no effect on VEGF mRNA. The RT-PCR 
data was not significant and the trend was that of the ARVM expression profile. 
We initially turned to VSMC because we hypothesized that they could contribute 
to the paracrine/autocrine activity similar to what we saw in the LV from the 
ARVM. It is unclear if VSMC play a role in HFpEF progression, but their lack of 
consistent response to aldosterone could potential explain the down regulation of 
VEGF-A we observed in the aorta of our HFpEF mice. We initially sough to test 
the hypothesis that VEGF-A plays a role in our HFpEF mouse model, what we 
found was that ARVM contribute to localized VEGF-A increased production in the 
LV while in the aorta there is a down regulation of VEGF-A in our HFpEF model, 
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we are unable to make any conclusion about VSMC response to aldosterone 
because of insufficient sample size. Thus in conclusion, it appears that VEGF-A 
does play a role in our HFpEF model specifically in a paracrine/autocrine manner 
in the LV where the ARVM contributes to the increased production of the 
cytokine.        
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